Last season, Baylor and TCU both finished 8-1 in the Big 12 and were deemed co-champions, even though the Bears beat the Horned Frogs. After the conference had touted its full round-robin schedule and ”One True Champion” slogan, the co-championship put the league and Commissioner Bob Bowlsby in an awkward spot.
– Denise McCluggage was godmother to all of us who write about cars. Reliable, caring, funny, kind, attentive, daring, adventurous, and a million other flattering adjectives aren’t enough to capture her character. She was always a fine writer, a great editor, and had a genius for friendship. And when she raced, she was fast. She was born in 1927, wrote about cars and the people who raced and loved them
Alberto Contador has said he has “good sensations” ahead of his bid to win the Giro d’Italia.
(Reuters) – Music streaming service Spotify is laying plans to enter the Web video business and has been in discussions with several digital media players about potential partnerships, the Wall Street Journal said, citing people familiar with the matter. The company has been reaching out to companies that specialize in making content for Google Inc’s YouTube to discuss both acquiring their material and co-creating original video series, the Journal said.
LOS ANGELES (AP) — NBC is adding the star power of Julia Roberts, Jennifer Aniston and Leslie Mann to its “Red Nose Day” charity special.
MISSOULA, Mont. (AP) — An audience gave the best-selling author of a book about a Montana city’s mishandling of rape cases a standing ovation and then booed a heckler who had elbowed his way to the stage and called Jon Krakauer a liar.
NEW YORK (AP) — That children’s fantasy of fighting alongside — instead of just watching — favorite superheroes like Iron Man and Spider-Man is a step closer.
Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company’s flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine’s exclusivity in Europe. The so-called polymorph patent in question would have kept cheaper versions of Revlimid off the European market until September 2024. The New Jersey-based biotechnology company said it plans to appeal the ruling, a process